State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Int J Mol Sci. 2023 Jan 18;24(3):1900. doi: 10.3390/ijms24031900.
The Zika virus (ZIKV) epidemic poses a significant threat to human health globally. Thus, there is an urgent need for developing effective anti-ZIKV agents. ZIKV non-structural protein 5 RNA-dependent RNA polymerase (RdRp), a viral enzyme for viral replication, has been considered an attractive drug target. In this work, we screened an anti-infection compound library and a natural product library by virtual screening to identify potential candidates targeting RdRp. Then, five selected candidates were further applied for RdRp enzymatic analysis, cytotoxicity, and binding examination by SPR. Finally, posaconazole (POS) was confirmed to effectively inhibit both RdRp activity with an IC of 4.29 μM and the ZIKV replication with an EC of 0.59 μM. Moreover, POS was shown to reduce RdRp activity by binding with the key amino acid D666 through molecular docking and site-directed mutation analysis. For the first time, our work found that POS could inhibit ZIKV replication with a stronger inhibitory activity than chloroquine. This work also demonstrated fast anti-ZIKV screening for inhibitors of RdRp and provided POS as a potential anti-ZIKV agent.
寨卡病毒(ZIKV)疫情对全球人类健康构成重大威胁。因此,迫切需要开发有效的抗 ZIKV 药物。ZIKV 非结构蛋白 5 RNA 依赖性 RNA 聚合酶(RdRp)是一种用于病毒复制的病毒酶,已被认为是一种有吸引力的药物靶标。在这项工作中,我们通过虚拟筛选对抗感染化合物库和天然产物库进行了筛选,以鉴定针对 RdRp 的潜在候选药物。然后,进一步对 5 种选定的候选药物进行 RdRp 酶分析、细胞毒性和 SPR 结合检测。最后,泊沙康唑(POS)被证实可有效抑制 RdRp 活性(IC50 为 4.29 μM)和 ZIKV 复制(EC50 为 0.59 μM)。此外,通过分子对接和定点突变分析,POS 被证明通过与关键氨基酸 D666 结合来降低 RdRp 活性。我们的工作首次发现 POS 可抑制 ZIKV 复制,其抑制活性强于氯喹。这项工作还展示了针对 RdRp 抑制剂的快速抗 ZIKV 筛选,并提供了 POS 作为一种潜在的抗 ZIKV 药物。